This HTML5 document contains 122 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n9http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00994/identifier/national-drug-code-directory/
n6http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n26http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/mixture/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00994/identifier/chebi/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00994/identifier/wikipedia/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00994/identifier/pharmgkb/
n24http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00994/identifier/pdb/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00994/identifier/kegg-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n25http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n29http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00994/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00994/identifier/drugbank/
n11http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00994
rdf:type
n3:Drug
n3:description
A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). Neomycin is a bactericidal aminoglycoside antibiotic that binds to the 30S ribosome of susceptible organisms. Binding interferes with mRNA binding and acceptor tRNA sites and results in the production of non-functional or toxic peptides.
n3:dosage
n14:271B4BBD-363D-11E5-9242-09173F13E4C5 n14:271B4BBC-363D-11E5-9242-09173F13E4C5 n14:271B4BBB-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
2 to 3 hours
n3:indication
Topical uses include treatment for superficial eye infections caused by susceptible bacteria (used in combination with other antiinfectives), treatment of otitis externa caused by susceptible bacteria, treatment or prevention of bacterial infections in skin lesions, and use as a continuous short-term irrigant or rinse to prevent bacteriuria and gram negative rod bacteremia in abacteriuric patients with indwelling catheters. May be used orally to treat hepatic encephalopathy, as a perioperative prophylactic agent, and as an adjunct to fluid and electrolyte replacement in the treatment of diarrhea caused to enteropathogenic E. coli (EPEC).
n3:manufacturer
n4:271B4BB3-363D-11E5-9242-09173F13E4C5 n4:271B4BB4-363D-11E5-9242-09173F13E4C5 n4:271B4BB1-363D-11E5-9242-09173F13E4C5 n4:271B4BB2-363D-11E5-9242-09173F13E4C5 n4:271B4BB5-363D-11E5-9242-09173F13E4C5 n4:271B4BB6-363D-11E5-9242-09173F13E4C5 n4:271B4BB0-363D-11E5-9242-09173F13E4C5 n4:271B4BAE-363D-11E5-9242-09173F13E4C5 n4:271B4BAF-363D-11E5-9242-09173F13E4C5 n4:271B4BAD-363D-11E5-9242-09173F13E4C5
owl:sameAs
n13:DB00994 n24:DB00994
dcterms:title
Neomycin
adms:identifier
n17:DB00994 n18:7507 n19:39822-0310-5 n20:CNY n21:C00384 n22:46505525 n23:PA450608 n28:Neomycin
n3:mechanismOfAction
Aminoglycosides like neomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically neomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.
n3:packager
n4:271B4B9F-363D-11E5-9242-09173F13E4C5 n4:271B4BAC-363D-11E5-9242-09173F13E4C5 n4:271B4BAA-363D-11E5-9242-09173F13E4C5 n4:271B4BAB-363D-11E5-9242-09173F13E4C5 n4:271B4BA8-363D-11E5-9242-09173F13E4C5 n4:271B4BA9-363D-11E5-9242-09173F13E4C5 n4:271B4BA6-363D-11E5-9242-09173F13E4C5 n4:271B4BA7-363D-11E5-9242-09173F13E4C5 n4:271B4BA4-363D-11E5-9242-09173F13E4C5 n4:271B4BA5-363D-11E5-9242-09173F13E4C5 n4:271B4BA2-363D-11E5-9242-09173F13E4C5 n4:271B4BA3-363D-11E5-9242-09173F13E4C5 n4:271B4BA0-363D-11E5-9242-09173F13E4C5 n4:271B4BA1-363D-11E5-9242-09173F13E4C5 n4:271B4B9E-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
The small absorbed fraction is rapidly distributed in the tissues and is excreted by the kidney in keeping with the degree of kidney function.
n3:toxicity
LD50 = 200 mg/kg (rat). Because of low absorption, it is unlikely that acute overdosage would occur with oral neomycin. However, prolonged administration could result in sufficient systemic drug levels to produce neurotoxicity, ototoxicity and/or nephrotoxicity. Nephrotoxicity occurs via drug accumulation in renal proximal tubular cells resulting in cellular damage. Tubular cells may regenerate despite continued exposure and nephrotoxicity is usually mild reversible. Neomycin is the most toxic aminoglycoside agent, which is thought to be due to its large number of cationic amino groups. Otoxocity occurs via drug accumulation in the endolymph and perilymph of the inner ear causing irreversible damage to hair cells in the cochlea or summit of ampullar cristae in the vestibular complex. High frequency hearing loss is followed by low frequency hearing loss. Further toxicity may cause retrograde degeneration of the auditory nerve. Vestibular toxicity may result in vertigo, nausea and vomiting, dizziness and loss of balance.
n5:hasAHFSCode
n6:84-04-04 n6:52-04-04
n3:mixture
n15:271B4B8B-363D-11E5-9242-09173F13E4C5 n15:271B4B8C-363D-11E5-9242-09173F13E4C5 n15:271B4B8F-363D-11E5-9242-09173F13E4C5 n15:271B4B90-363D-11E5-9242-09173F13E4C5 n15:271B4B8D-363D-11E5-9242-09173F13E4C5 n15:271B4B8E-363D-11E5-9242-09173F13E4C5 n15:271B4B93-363D-11E5-9242-09173F13E4C5 n15:271B4B94-363D-11E5-9242-09173F13E4C5 n15:271B4B91-363D-11E5-9242-09173F13E4C5 n15:271B4B92-363D-11E5-9242-09173F13E4C5 n15:271B4B99-363D-11E5-9242-09173F13E4C5 n15:271B4B9A-363D-11E5-9242-09173F13E4C5 n15:271B4B95-363D-11E5-9242-09173F13E4C5 n15:271B4B98-363D-11E5-9242-09173F13E4C5 n15:271B4B9D-363D-11E5-9242-09173F13E4C5 n15:271B4B9B-363D-11E5-9242-09173F13E4C5 n15:271B4B9C-363D-11E5-9242-09173F13E4C5 n15:271B4B96-363D-11E5-9242-09173F13E4C5 n15:271B4B97-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Protein binding studies have shown that the degree of aminoglycoside protein binding is low and, depending upon the methods used for testing, may be between 0% and 30%.
n3:salt
n3:synthesisReference
Jaehoon Yu, Jongkook Lee, Miyun Kwon, Ae Pae, Hun Koh, "Heterodimeric conjugates of neomycin-oxazolidinone, their preparation and their use." U.S. Patent US20050222055, issued October 06, 2005.
n25:hasConcept
n26:M0014565
foaf:page
n9:neomy.htm n29:neomycin.html
n3:IUPAC-Name
n7:271B4BC2-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B4BC8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B4BC7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B4BC4-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B4BC5-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B4BC6-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B4BC0-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B4BD9-363D-11E5-9242-09173F13E4C5 n7:271B4BC1-363D-11E5-9242-09173F13E4C5 n7:271B4BBE-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B4BBF-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n11:S01AA03 n11:R02AB01 n11:A01AB08 n11:S02AA07 n11:D06AX04 n11:J01GB05 n11:A07AA01 n11:S03AA01 n11:B05CA09
n3:H-Bond-Acceptor-Count
n7:271B4BCE-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B4BCF-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B4BC9-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B4BCA-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B4BCC-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B4BCB-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B4BCD-363D-11E5-9242-09173F13E4C5
n3:absorption
Poorly absorbed from the normal gastrointestinal tract. Although only approximately 3% of neomycin is absorbed through intact intestinal mucosa, significant amounts may be absorbed through ulcerated or denuded mucosa or if inflammation is present.
n3:affectedOrganism
Escherichia coli Enterobacter Enteric bacteria and other eubacteria Klebsiella
n3:casRegistryNumber
1404-04-2
n3:category
n3:containedIn
n10:271B4BBA-363D-11E5-9242-09173F13E4C5 n10:271B4BB9-363D-11E5-9242-09173F13E4C5 n10:271B4BB7-363D-11E5-9242-09173F13E4C5 n10:271B4BB8-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B4BD4-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B4BD6-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B4BD7-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B4BD8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B4BD3-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B4BD2-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B4BD5-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B4BC3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n7:271B4BD0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B4BD1-363D-11E5-9242-09173F13E4C5